/
Our Company We are a global leader in biosimulation science, technology, and consulting services for using Model-Informed Drug Development ( MIDD ) in the global biopharmaceutical and biotech industry. MIDD is an approach that utilizes biological and statistical models derived from preclinical, clinical, and evidence data to inform decision-making in drug research and development, and commercia…
$5.60
$0.02 (-0.36%)
Price from 2 days ago
Operating margin is thin at 5.03%. Limited cushion if revenue slows or costs rise, not the profile of a wide-moat business.
Revenue grew 8.9%, steady but not accelerating.
Insufficient data to identify specific risks. Treat any missing metrics as a data gap, not a clean bill of health.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$419M
▲ +8.9% YoY
Net Income (TTM)
-$15M
▲ +86.8% YoY
Op. Margin
2.17%
▲ +5.5pp YoY
ROIC
0.53%
▲ +1.0pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
$89M
▲ +19.9% YoY
Op. Cash Flow (TTM)
$91M
▲ +19.7% YoY
Net Debt
$154M
Cash & Equiv.
$149M
5Y CAGR: +11.4%
5Y CAGR: +16.6%
Continue Research